Instruction 1(b)

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average burden										
hours per response:	0.5									

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* <u>Kintz Samuel</u>						2. Issuer Name and Ticker or Trading Symbol Enliven Therapeutics, Inc. [ELVN]									k all applic Directo	able) r	ng Pers	on(s) to Iss	wner	
(Last) (First) (Middle) C/O ENLIVEN THERAPEUTICS, INC.					3. Date of Earliest Transaction (Month/Day/Year) 09/25/2023								X Officer (give title below) Other (specify below) President and CEO					specify		
6200 LOOKOUT ROAD					4.	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)						
(Street) BOULDER CO 80301															X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(City) (State) (Zip)			R	Rule 10b5-1(c) Transaction Indication															
						Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.														
		Tab	le I -	Non-Der	ivativ	e Sec	curit	ies A	cquir	ed, D	isposed o	of, or E	Benefici	ally	Owned					
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Ye				Execution Date,		3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and			(A) or 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following		Form:	Direct I Indirect E tr. 4)	7. Nature of ndirect Beneficial Dwnership					
								Code	v	Amount	(A) or (D)	Price		Reported Transaction(s) (Instr. 3 and 4)				Instr. 4)		
Common Stock			09/25/2	2023				M ⁽¹⁾		12,000	A	\$1.12	2	12,000		D				
Common	Stock			09/25/2	2023				S ⁽¹⁾		12,000	D	\$13.807	⁷⁶⁽²⁾	0 D			D		
Common	Stock													I 1 087 525 I I I					See Cootnote ⁽³⁾	
Common Stock														88,	531			See Cootnote ⁽⁴⁾		
Common Stock															88,531			1 1	See Cootnote ⁽⁵⁾	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) Date (Month/Day/Year) (Month/Day/Year) 3. Deemed Execution Date, if any (Month/Day/Year) (Month/Day/Year) 4. Transaction Code (Instr. 8) Securities Acquirer (A) or Dispose of (D) (In 3, 4 and				vative urities uired or osed o) (Instr.	6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Ar of Securities Underlying Derivative Sec (Instr. 3 and 4)					S	. Price of erivative ecurity nstr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)				
				Code	v	(A)	(D)	Date Exercisable		Expiration Date	Title	Amour or Number of Shares	er							
Stock Option (right to buy)	\$1.12	09/25/2023			M			12,000		(6)	06/15/2030	Commo		00	\$0.00	332,5	50	D		

Explanation of Responses:

- 1. The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023.
- 2. This transaction was executed in multiple trades at prices ranging from \$13.11 to \$14.095. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- 3. The shares are held of record by The Kintz & Egan Trust Dated March 30, 2019 for which the reporting person serves as trustee.
- 4. The shares held of record by an irrevocable trust dated October 26, 2021 for the benefit of the Reporting Person's elder son and for which the Reporting Person serves as an investment advisor.
- 5. The shares held of record by an irrevocable trust dated October 26, 2021 for the benefit of the Reporting Person's younger son and for which the Reporting Person serves as an investment advisor.
- 6. The option, originally for 344,550 shares, is subject to an early exercise provision and is immediately exercisable. Shares subject to the option vest in 48 equal monthly installments beginning on May 3, 2020.

Remarks:

/s/ Ben Hohl, by power of 09/26/2023 <u>attorney</u>

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.